ADVERTISEMENT
2 /3 FREE ARTICLES LEFT THIS MONTH Remaining
Chemistry matters. Join us to get the news you need.

If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.

ENJOY UNLIMITED ACCES TO C&EN

Start-ups

Cullgen raises $16 million series A for targeted protein degraders

by Ryan Cross
April 20, 2019 | APPEARED IN VOLUME 97, ISSUE 16

 

San Diego–based Cullgen is the latest start-up launching with plans to develop targeted protein degraders—small molecules that bind a disease-causing protein at one end and tag it for destruction by the cell’s protein-recycling machinery at the other end. The venture capital firms Sequoia Capital China and HighLight Capital together invested $16 million in Cullgen’s series A financing. Cullgen’s initial focus is on cancer, as well as autoimmune and inflammatory diseases.

X

Article:

This article has been sent to the following recipient:

Leave A Comment

*Required to comment